Elicio Therapeutics Reports Preliminary Relapse-Free Survival Data From Ongoing Phase 1 Study Of Its Lead Asset, ELI-002
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics has reported preliminary relapse-free survival data from its ongoing Phase 1 study of its lead asset, ELI-002.
September 27, 2023 | 9:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elicio Therapeutics' ongoing Phase 1 study of ELI-002 has reported preliminary relapse-free survival data. This could potentially impact the company's stock.
Positive preliminary data from a Phase 1 study can be a significant catalyst for biotech stocks. As ELI-002 is Elicio's lead asset, this news is highly relevant and could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100